valvular heart disease - school of medicinevalvular heart disease ihab alomari, md, facc assistant...
TRANSCRIPT
Valvular Heart Disease
Ihab Alomari, MD, FACC Assistant Professor of Medicine Associate Director, Interventional Cardiology Fellowship Division of Cardiovascular Diseases University of California -Irvine
22
Core Valve Specifics
Nitinol self expanding frame • One frame with three different diameters and radial/hoop
strengths. Porcine Pericardial Tissue • Leaflets and skirt elements
– Fixation and sterilization • Valve 26 mm, 29 mm, 31 mm • Partially repositionable
Study started in the U.S. in 2010.
26
PARTNER Inclusion Criteria
Severe AS: Echo-derived AVA < 0.8 cm2 (or AVA index < 0.5 cm2/m2) and mean AVG > 40 mm Hg or peak jet velocity > 4.0 m/s
Cardiac Symptoms: NYHA Functional Class ≥ II
High surgical risk: Predicted risk of operative mortality ≥ 15% (determined by site surgeon and cardiologist); STS score ≥ 10
Inoperable patients: Predicted risk of 30 day mortality ≥ 50% post-surgery or a serious irreversible condition. • ≥ 2 surgeons agreement that patient is inoperable.